- Home
- RIGL vs CYRX Comparison
RIGL vs CYRX Comparison
Compare RIGL & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- CYRX
- Stock Information
- Founded
- RIGL 1996
- CYRX 1999
- Country
- RIGL United States
- CYRX United States
- Employees
- RIGL N/A
- CYRX N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- CYRX Health Care
- Exchange
- RIGL Nasdaq
- CYRX Nasdaq
- Market Cap
- RIGL 335.5M
- CYRX 365.5M
- IPO Year
- RIGL 2000
- CYRX N/A
- Fundamental
- Price
- RIGL $18.98
- CYRX $7.55
- Analyst Decision
- RIGL Buy
- CYRX Strong Buy
- Analyst Count
- RIGL 5
- CYRX 9
- Target Price
- RIGL $36.40
- CYRX $10.67
- AVG Volume (30 Days)
- RIGL 206.5K
- CYRX 546.4K
- Earning Date
- RIGL 08-05-2025
- CYRX 08-05-2025
- Dividend Yield
- RIGL N/A
- CYRX N/A
- EPS Growth
- RIGL N/A
- CYRX N/A
- EPS
- RIGL 2.08
- CYRX N/A
- Revenue
- RIGL $203,077,000.00
- CYRX $232,134,000.00
- Revenue This Year
- RIGL $14.41
- CYRX N/A
- Revenue Next Year
- RIGL $15.97
- CYRX $9.63
- P/E Ratio
- RIGL $9.41
- CYRX N/A
- Revenue Growth
- RIGL 70.16
- CYRX 11.75
- 52 Week Low
- RIGL $8.10
- CYRX $4.58
- 52 Week High
- RIGL $29.82
- CYRX $9.78
- Technical
- Relative Strength Index (RSI)
- RIGL 45.79
- CYRX 59.40
- Support Level
- RIGL $18.24
- CYRX $7.20
- Resistance Level
- RIGL $19.38
- CYRX $7.81
- Average True Range (ATR)
- RIGL 0.77
- CYRX 0.40
- MACD
- RIGL -0.04
- CYRX 0.01
- Stochastic Oscillator
- RIGL 43.64
- CYRX 77.22
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.